{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T08:24:28Z","timestamp":1794817468457,"version":"4.9.1"},"publisher-location":"Cham","reference-count":95,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031972416","type":"print"},{"value":"9783031972423","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-97242-3_12","type":"book-chapter","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T20:23:48Z","timestamp":1755894228000},"page":"267-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advancing Prostate Cancer Treatment: Innovations and Challenges in Immunotherapy"],"prefix":"10.1007","author":[{"given":"Gargi","family":"Singhal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atish","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarsan Vishnu","family":"Kollimuttathuillam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deric","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bamidele A.","family":"Adesunloye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6415-8160","authenticated-orcid":false,"given":"Sharad S.","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"issue":"2","key":"12_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63\u201389. https:\/\/doi.org\/10.14740\/wjon1191.","journal-title":"World J Oncol"},{"key":"12_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/RRU.S303215","volume":"14","author":"E Choi","year":"2022","unstructured":"Choi E, Buie J, Camacho J, Sharma P, de Riese WTW. Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers. Res Rep Urol. 2022;14:87\u2013108. https:\/\/doi.org\/10.2147\/RRU.S303215.","journal-title":"Res Rep Urol"},{"issue":"21","key":"12_CR3","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.3390\/jcm13216537","volume":"13","author":"P Garg","year":"2024","unstructured":"Garg P, Pareek S, Kulkarni P, Horne D, Salgia R, Singhal SS. Next-generation immunotherapy: advancing clinical applications in cancer treatment. J Clin Med. 2024;13(21):6537. https:\/\/doi.org\/10.3390\/jcm13216537.","journal-title":"J Clin Med"},{"issue":"4","key":"12_CR4","first-page":"210","volume":"10","author":"I Wang","year":"2022","unstructured":"Wang I, Song L, Wang BY, Rezazadeh Kalebasty A, Uchio E, Zi X. Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy. Am J Clin Exp Urol. 2022;10(4):210\u201333.","journal-title":"Am J Clin Exp Urol"},{"issue":"2","key":"12_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/cancers13020173","volume":"13","author":"M Adamaki","year":"2021","unstructured":"Adamaki M, Zoumpourlis V. Immunotherapy as a precision medicine tool for the treatment of prostate cancer. Cancer. 2021;13(2):173. https:\/\/doi.org\/10.3390\/cancers13020173.","journal-title":"Cancer"},{"issue":"1","key":"12_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.22465\/juo.234600100005","volume":"21","author":"JE Kim","year":"2023","unstructured":"Kim JE, Lee K, Kim IY. Current update on prostate cancer immunotherapy. J Urol Oncol. 2023;21(1):14\u201322. https:\/\/doi.org\/10.22465\/juo.234600100005.","journal-title":"J Urol Oncol"},{"issue":"2","key":"12_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/imm.13456","volume":"168","author":"D Feng","year":"2023","unstructured":"Feng D, Xiong Q, Wei Q, Yang L. Cellular landscape of tumour microenvironment in prostate cancer. Immunology. 2023;168(2):199\u2013202. https:\/\/doi.org\/10.1111\/imm.13456.","journal-title":"Immunology"},{"key":"12_CR8","doi-asserted-by":"publisher","unstructured":"Novysedlak R, Guney M, Al Khouri M, Bartolini R, Koumbas Foley L, Benesova I, Ozaniak A, Novak V, Vesely S, Pacas P, Buchler T, Ozaniak Strizova Z. The immune microenvironment in prostate cancer: a comprehensive review. Oncology. 2024:1\u201325. Advance online publication. https:\/\/doi.org\/10.1159\/000541881.","DOI":"10.1159\/000541881"},{"key":"12_CR9","doi-asserted-by":"publisher","first-page":"1199173","DOI":"10.3389\/fimmu.2023.1199173","volume":"14","author":"YL Yang","year":"2023","unstructured":"Yang YL, Yang F, Huang ZQ, Li YY, Shi HY, Sun Q, Ma Y, Wang Y, Zhang Y, Yang S, Zhao GR, Xu FH. T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems. Front Immunol. 2023;14:1199173. https:\/\/doi.org\/10.3389\/fimmu.2023.1199173.","journal-title":"Front Immunol"},{"issue":"2","key":"12_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/biology12020218","volume":"12","author":"S Dutta","year":"2023","unstructured":"Dutta S, Ganguly A, Chatterjee K, Spada S, Mukherjee S. Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors. Biology. 2023;12(2):218. https:\/\/doi.org\/10.3390\/biology12020218.","journal-title":"Biology"},{"key":"12_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W, et al. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8:9. https:\/\/doi.org\/10.1038\/s41392-022-01270-x.","journal-title":"Signal Transduct Target Ther"},{"key":"12_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844866","volume":"13","author":"BC Taylor","year":"2022","unstructured":"Taylor BC, Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol. 2022;13:844866. https:\/\/doi.org\/10.3389\/fimmu.2022.844866.","journal-title":"Front Immunol"},{"issue":"2\u20133","key":"12_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10555-013-9479-8","volume":"33","author":"MT Schweizer","year":"2014","unstructured":"Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev. 2014;33(2\u20133):641\u201355. https:\/\/doi.org\/10.1007\/s10555-013-9479-8.","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"12_CR14","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","volume":"17","author":"MA Cheever","year":"2011","unstructured":"Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17(11):3520\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-3126.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"12_CR15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/jnci\/djaa021","volume":"112","author":"RA Madan","year":"2020","unstructured":"Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL. Putting the pieces together: completing the mechanism of action jigsaw for Sipuleucel-T. J Natl Cancer Inst. 2020;112(6):562\u201373. https:\/\/doi.org\/10.1093\/jnci\/djaa021.","journal-title":"J Natl Cancer Inst"},{"key":"12_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12645-015-0010-5","volume":"6","author":"G Cole","year":"2015","unstructured":"Cole G, McCaffrey J, Ali AA, et al. DNA vaccination for prostate cancer: key concepts and considerations. Cancer Nano. 2015;6:2. https:\/\/doi.org\/10.1186\/s12645-015-0010-5.","journal-title":"Cancer Nano"},{"issue":"3","key":"12_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.20517\/cdr.2022.15","volume":"5","author":"A Yehya","year":"2022","unstructured":"Yehya A, Ghamlouche F, Zahwe A, Zeid Y, Wakimian K, Mukherji D, Abou-Kheir W. Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo. Cancer Drug Resist. 2022;5(3):667\u201390. https:\/\/doi.org\/10.20517\/cdr.2022.15.","journal-title":"Cancer Drug Resist"},{"issue":"12","key":"12_CR18","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.3390\/vaccines12121384","volume":"12","author":"W Zhou","year":"2024","unstructured":"Zhou W, Lu X, Tian F, Luo Q, Zhou W, Yang S, Li W, Yang Y, Shi M, Zhou T. Vaccine therapies for prostate cancer: current status and future outlook. Vaccine. 2024;12(12):1384. https:\/\/doi.org\/10.3390\/vaccines12121384.","journal-title":"Vaccine"},{"issue":"5","key":"12_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.urolonc.2005.08.021","volume":"24","author":"JW Simons","year":"2006","unstructured":"Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol. 2006;24(5):419\u201324. https:\/\/doi.org\/10.1016\/j.urolonc.2005.08.021.","journal-title":"Urol Oncol"},{"issue":"17","key":"12_CR20","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/cells12172159","volume":"12","author":"M Kaczmarek","year":"2023","unstructured":"Kaczmarek M, Pozna\u0144ska J, Fechner F, Michalska N, Paszkowska S, Napiera\u0142a A, Mackiewicz A. Cancer vaccine therapeutics: limitations and effectiveness\u2014a literature review. Cells. 2023;12(17):2159. https:\/\/doi.org\/10.3390\/cells12172159.","journal-title":"Cells"},{"issue":"1","key":"12_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","volume":"23","author":"HE Marei","year":"2023","unstructured":"Marei HE, Hasan A, Pozzoli G, Cenciarelli C. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int. 2023;23(1):64. https:\/\/doi.org\/10.1186\/s12935-023-02902-0.","journal-title":"Cancer Cell Int"},{"issue":"9","key":"12_CR22","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1172\/JCI80012","volume":"125","author":"E Buchbinder","year":"2015","unstructured":"Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015;125(9):3377\u201383. https:\/\/doi.org\/10.1172\/JCI80012.","journal-title":"J Clin Invest"},{"issue":"1","key":"12_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/fon.14.196","volume":"11","author":"Z Reese","year":"2015","unstructured":"Reese Z, Straubhar A, Pal SK, Agarwal N. Ipilimumab in the treatment of prostate cancer. Future Oncol. 2015;11(1):27\u201337. https:\/\/doi.org\/10.2217\/fon.14.196.","journal-title":"Future Oncol"},{"issue":"5","key":"12_CR24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/17512433.2018.1464388","volume":"11","author":"P Isaacsson Velho","year":"2018","unstructured":"Isaacsson Velho P, Antonarakis ES. PD-1\/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol. 2018;11(5):475\u201386. https:\/\/doi.org\/10.1080\/17512433.2018.1464388.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"13","key":"12_CR25","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.3390\/cancers16132478","volume":"16","author":"P Garg","year":"2024","unstructured":"Garg P, Malhotra J, Kulkarni P, Horne D, Salgia R, Singhal SS. Emerging therapeutic strategies to overcome drug resistance in cancer cells. Cancer. 2024;16(13):2478. https:\/\/doi.org\/10.3390\/cancers16132478.","journal-title":"Cancer"},{"issue":"4","key":"12_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2012","unstructured":"Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269\u201381. https:\/\/doi.org\/10.1038\/nri3191.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"12_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/ejh.14074","volume":"112","author":"M Ho","year":"2024","unstructured":"Ho M, Zanwar S, Paludo J. Chimeric antigen receptor T-cell therapy in hematologic malignancies: successes, challenges, and opportunities. Eur J Hematol. 2024;112(2):197\u2013210. https:\/\/doi.org\/10.1111\/ejh.14074.","journal-title":"Eur J Hematol"},{"issue":"1","key":"12_CR28","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1186\/s12967-024-05703-9","volume":"22","author":"EA Golikova","year":"2024","unstructured":"Golikova EA, Alshevskaya AA, Alrhmoun S, Sivitskaya NA, Sennikov SV. TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges. J Transl Med. 2024;22(1):897. https:\/\/doi.org\/10.1186\/s12967-024-05703-9.","journal-title":"J Transl Med"},{"key":"12_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev.iy.13.040195.001343","volume":"13","author":"G Trinchieri","year":"1995","unstructured":"Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 1995;13:251\u201376. https:\/\/doi.org\/10.1146\/annurev.iy.13.040195.001343.","journal-title":"Annu Rev Immunol"},{"key":"12_CR30","doi-asserted-by":"publisher","first-page":"1090311","DOI":"10.3389\/fimmu.2023.1090311","volume":"14","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Quan G, Liu Y, Shi N, Wu Y, Zhang R, Gao X, Luo L. The application of interleukin-2 family cytokines in tumor immunotherapy research. Front Immunol. 2023;14:1090311. https:\/\/doi.org\/10.3389\/fimmu.2023.1090311.","journal-title":"Front Immunol"},{"issue":"15","key":"12_CR31","doi-asserted-by":"publisher","first-page":"8035","DOI":"10.3390\/ijms22158035","volume":"22","author":"CG Kim","year":"2021","unstructured":"Kim CG, Sang YB, Lee JH, Chon HJ. Combining cancer vaccines with immunotherapy: establishing a new immunological approach. Int J Mol Sci. 2021;22(15):8035. https:\/\/doi.org\/10.3390\/ijms22158035.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"12_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4062\/biomolther.2023.196","volume":"32","author":"K Song","year":"2024","unstructured":"Song K. Current development status of cytokines for cancer immunotherapy. Biomol Ther. 2024;32(1):13\u201324. https:\/\/doi.org\/10.4062\/biomolther.2023.196.","journal-title":"Biomol Ther"},{"issue":"23","key":"12_CR33","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1002\/cncr.30250","volume":"122","author":"BT Rekoske","year":"2016","unstructured":"Rekoske BT, McNeel DG. Immunotherapy for prostate cancer: false promises or true hope? Cancer. 2016;122(23):3598\u2013607. https:\/\/doi.org\/10.1002\/cncr.30250.","journal-title":"Cancer"},{"key":"12_CR34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2017.00202","volume":"7","author":"SR Jhawar","year":"2017","unstructured":"Jhawar SR, Thandoni A, Bommareddy PK, Hassan S, Kohlhapp FJ, Goyal S, Schenkel JM, Silk AW, Zloza A. Oncolytic viruses-natural and genetically engineered cancer immunotherapies. Front Oncol. 2017;7:202. https:\/\/doi.org\/10.3389\/fonc.2017.00202.","journal-title":"Front Oncol"},{"issue":"9","key":"12_CR35","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642\u201362. https:\/\/doi.org\/10.1038\/nrd4663.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"12_CR36","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","volume":"188","author":"JM Burke","year":"2012","unstructured":"Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, Maslyar DJ, McKiernan JM. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012;188(6):2391\u20137. https:\/\/doi.org\/10.1016\/j.juro.2012.07.097.","journal-title":"J Urol"},{"issue":"12","key":"12_CR37","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.3390\/biomedicines10123262","volume":"10","author":"K Yang","year":"2022","unstructured":"Yang K, Feng S, Luo Z. Oncolytic adenovirus, a new treatment strategy for prostate cancer. Biomedicine. 2022;10(12):3262. https:\/\/doi.org\/10.3390\/biomedicines10123262.","journal-title":"Biomedicine"},{"issue":"7","key":"12_CR38","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/14760584.2021.1951246","volume":"21","author":"N Ebrahimi","year":"2022","unstructured":"Ebrahimi N, Akbari M, Ghanaatian M, Roozbahani Moghaddam P, Adelian S, Borjian Boroujeni M, Yazdani E, Ahmadi A, Hamblin MR. Development of neoantigens: from identification in cancer cells to application in cancer vaccines. Expert Rev Vaccines. 2022;21(7):941\u201355. https:\/\/doi.org\/10.1080\/14760584.2021.1951246.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"12_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215\u201329. https:\/\/doi.org\/10.1038\/s41571-020-00460-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"12_CR40","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-20-1575","volume":"11","author":"RG Gupta","year":"2021","unstructured":"Gupta RG, Li F, Roszik J, Liz\u00e9e G. Exploiting tumor neoantigens to target cancer evolution: current challenges and promising therapeutic approaches. Cancer Discov. 2021;11(5):1024\u201339. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1575.","journal-title":"Cancer Discov"},{"issue":"4","key":"12_CR41","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00432-019-02867-6","volume":"145","author":"L Yu","year":"2019","unstructured":"Yu L, Wang J. T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances. J Cancer Res Clin Oncol. 2019;145(4):941\u201356. https:\/\/doi.org\/10.1007\/s00432-019-02867-6.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"12_CR42","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1021\/acsptsci.3c00159","volume":"6","author":"G Das","year":"2023","unstructured":"Das G, Ptacek J, Havlinova B, Nedvedova J, Barinka C, Novakova Z. Targeting prostate cancer using bispecific T-cell engagers against prostate-specific membrane antigen. ACS Pharmacol Transl Sci. 2023;6(11):1703\u201314. https:\/\/doi.org\/10.1021\/acsptsci.3c00159.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"12_CR43","doi-asserted-by":"publisher","first-page":"1035276","DOI":"10.3389\/fimmu.2022.1035276","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022;13:1035276. https:\/\/doi.org\/10.3389\/fimmu.2022.1035276.","journal-title":"Front Immunol"},{"issue":"10","key":"12_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101199","volume":"4","author":"D Sridaran","year":"2023","unstructured":"Sridaran D, Bradshaw E, DeSelm C, Pachynski R, Mahajan K, Mahajan NP. Prostate cancer immunotherapy: improving clinical outcomes with a multi-pronged approach. Cell Rep Med. 2023;4(10):101199. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101199.","journal-title":"Cell Rep Med"},{"issue":"8","key":"12_CR45","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3390\/biomedicines10081778","volume":"10","author":"P Xu","year":"2022","unstructured":"Xu P, Wasielewski LJ, Yang JC, Cai D, Evans CP, Murphy WJ, Liu C. The immunotherapy and immunosuppressive signaling in therapy-resistant prostate cancer. Biomedicine. 2022;10(8):1778. https:\/\/doi.org\/10.3390\/biomedicines10081778.","journal-title":"Biomedicine"},{"key":"12_CR46","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3389\/fimmu.2018.01364","volume":"9","author":"T Komai","year":"2018","unstructured":"Komai T, Inoue M, Okamura T, Morita K, Iwasaki Y, Sumitomo S, Shoda H, Yamamoto K, Fujio K. Transforming growth factor-\u03b2 and interleukin-10 synergistically regulate humoral immunity via modulating metabolic signals. Front Immunol. 2018;9:1364. https:\/\/doi.org\/10.3389\/fimmu.2018.01364.","journal-title":"Front Immunol"},{"key":"12_CR47","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.csbj.2019.03.015","volume":"17","author":"AP George","year":"2019","unstructured":"George AP, Kuzel TM, Zhang Y, Zhang B. The discovery of biomarkers in cancer immunotherapy. Comput Struct Biotechnol J. 2019;17:484\u201397. https:\/\/doi.org\/10.1016\/j.csbj.2019.03.015.","journal-title":"Comput Struct Biotechnol J"},{"key":"12_CR48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","volume":"12","author":"P Zhao","year":"2019","unstructured":"Zhao P, Li L, Jiang X, et al. Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12:54. https:\/\/doi.org\/10.1186\/s13045-019-0738-1.","journal-title":"J Hematol Oncol"},{"key":"12_CR49","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, Bai L, Bian Y. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975. https:\/\/doi.org\/10.3389\/fimmu.2023.1167975.","journal-title":"Front Immunol"},{"issue":"36","key":"12_CR50","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073\u2013126. https:\/\/doi.org\/10.1200\/JCO.21.01440.","journal-title":"J Clin Oncol"},{"issue":"12","key":"12_CR51","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.3390\/biomedicines12122787","volume":"12","author":"AH Alshammari","year":"2024","unstructured":"Alshammari AH, Hirotsu T, di Luccio E. Overcoming challenges in cancer care: a focus on emerging technologies. Biomedicine. 2024;12(12):2787. https:\/\/doi.org\/10.3390\/biomedicines12122787.","journal-title":"Biomedicine"},{"key":"12_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113137","volume":"142","author":"G Qiannan","year":"2024","unstructured":"Qiannan G, Anning Q, Ne W, Zhenxian Z, Xiaohui Z. Unlocking immunity: innovative prostate cancer vaccine strategies. Int Immunopharmacol. 2024;142:113137.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"12_CR53","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2008.10.008","volume":"55","author":"H Isbarn","year":"2009","unstructured":"Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol. 2009;55(1):62\u201375. https:\/\/doi.org\/10.1016\/j.eururo.2008.10.008.","journal-title":"Eur Urol"},{"issue":"13","key":"12_CR54","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-19-3372","volume":"26","author":"AZ Obradovic","year":"2020","unstructured":"Obradovic AZ, Dallos MC, Zahurak ML, Partin AW, Schaeffer EM, Ross AE, Allaf ME, Nirschl TR, Liu D, Chapman CG. T-cell infiltration and adaptive Treg resistance in response to androgen deprivation with or without vaccination in localized prostate cancer. Clin Cancer Res. 2020;26(13):3182\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3372.","journal-title":"Clin Cancer Res"},{"key":"12_CR55","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41419-024-06837-w","volume":"15","author":"P Yu","year":"2024","unstructured":"Yu P, Zhu C, You X, et al. The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies. Cell Death Dis. 2024;15:433. https:\/\/doi.org\/10.1038\/s41419-024-06837-w.","journal-title":"Cell Death Dis"},{"key":"12_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.744679","volume":"11","author":"L Ollivier","year":"2021","unstructured":"Ollivier L, Labb\u00e9 M, Fradin D, Potiron V, Supiot S. Interaction between modern radiotherapy and immunotherapy for metastatic prostate cancer. Front Oncol. 2021;11:744679. https:\/\/doi.org\/10.3389\/fonc.2021.744679.","journal-title":"Front Oncol"},{"issue":"8","key":"12_CR57","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","volume":"39","author":"ME Rodr\u00edguez-Ruiz","year":"2018","unstructured":"Rodr\u00edguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 2018;39(8):644\u201355. https:\/\/doi.org\/10.1016\/j.it.2018.06.001.","journal-title":"Trends Immunol"},{"issue":"5","key":"12_CR58","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.ijrobp.2021.08.009","volume":"111","author":"EH Akama-Garren","year":"2021","unstructured":"Akama-Garren EH, Morris ZS, Sikora AG, Weichselbaum R, Schoenfeld JD. Prospective clinical investigation of the efficacy of combination radiation therapy with immune checkpoint inhibition. Int J Radiat Oncol Biol Phys. 2021;111(5):1165\u201375. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.08.009.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"12_CR59","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1644109","volume":"8","author":"H Taghizadeh","year":"2019","unstructured":"Taghizadeh H, Marhold M, Tomasich E, Udovica S, Merchant A, Krainer M. Immune checkpoint inhibitors in mCRPC\u2014rationales, challenges and perspectives. Onco Targets Ther. 2019;8(11):e1644109. https:\/\/doi.org\/10.1080\/2162402X.2019.1644109.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"12_CR60","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1634\/theoncologist.2020-0697","volume":"26","author":"EN Risdon","year":"2021","unstructured":"Risdon EN, Chau CH, Price DK, Sartor O, Figg WD. PARP inhibitors and prostate cancer: to infinity and beyond BRCA. Oncologist. 2021;26(1):e115\u201329. https:\/\/doi.org\/10.1634\/theoncologist.2020-0697.","journal-title":"Oncologist"},{"issue":"11","key":"12_CR61","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 2018;25(11):2972\u20132980.e5. https:\/\/doi.org\/10.1016\/j.celrep.2018.11.054.","journal-title":"Cell Rep"},{"key":"12_CR62","doi-asserted-by":"publisher","first-page":"175883592094411","DOI":"10.1177\/1758835920944116","volume":"12","author":"EK Lee","year":"2020","unstructured":"Lee EK, Konstantinopoulos PA. PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers. Ther Adv Med Oncol. 2020;12:1758835920944116. https:\/\/doi.org\/10.1177\/1758835920944116.","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"12_CR63","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1007\/s12325-024-02844-7","volume":"41","author":"Y Fan","year":"2024","unstructured":"Fan Y, Liu Z, Chen Y, He Z. Homologous recombination repair gene mutations in prostate cancer: prevalence and clinical value. Adv Ther. 2024;41(6):2196\u2013216. https:\/\/doi.org\/10.1007\/s12325-024-02844-7.","journal-title":"Adv Ther"},{"issue":"8","key":"12_CR64","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/1758834017719215","volume":"9","author":"N Terada","year":"2017","unstructured":"Terada N, Akamatsu S, Kobayashi T, Inoue T, Ogawa O, Antonarakis ES. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2017;9(8):565\u201373. https:\/\/doi.org\/10.1177\/1758834017719215.","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"12_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189106","volume":"1879","author":"P Garg","year":"2024","unstructured":"Garg P, Krishna M, Subbalakshmi AR, Ramisetty S, Mohanty A, Kulkarni P, Horne D, Salgia R, Singhal SS. Emerging biomarkers and molecular targets for precision medicine in cervical cancer. Biochim Biophys Acta Rev Cancer. 2024;1879(3):189106. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189106.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"22","key":"12_CR66","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.3390\/cancers13225723","volume":"13","author":"S Asif","year":"2021","unstructured":"Asif S, Teply BA. Biomarkers for treatment response in advanced prostate cancer. Cancer. 2021;13(22):5723. https:\/\/doi.org\/10.3390\/cancers13225723.","journal-title":"Cancer"},{"issue":"Suppl 2","key":"12_CR67","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4137\/BIC.S31802","volume":"8","author":"PO Gaudreau","year":"2016","unstructured":"Gaudreau PO, Stagg J, Souli\u00e8res D, Saad F. The present and future of biomarkers in prostate cancer: proteomics, genomics, and immunology advancements. Biomarkers Cancer. 2016;8(Suppl 2):15\u201333. https:\/\/doi.org\/10.4137\/BIC.S31802.","journal-title":"Biomarkers Cancer"},{"issue":"4","key":"12_CR68","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847\u201356. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0983.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"12_CR69","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154\u201373. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.001.","journal-title":"Cancer Cell"},{"issue":"1","key":"12_CR70","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/mc.23442","volume":"62","author":"S Coleman","year":"2023","unstructured":"Coleman S, Xie M, Tarhini AA, Tan AC. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma. Mol Carcinog. 2023;62(1):77\u201389. https:\/\/doi.org\/10.1002\/mc.23442.","journal-title":"Mol Carcinog"},{"key":"12_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.729359","volume":"12","author":"H Ji","year":"2021","unstructured":"Ji H, Ba Y, Ma S, Hou K, Mi S, Gao X, Jin J, Gong Q, Liu T, Wang F, Liu Z, Li S, Du J, Hu S. Construction of interferon-gamma-related gene signature to characterize the immune-inflamed phenotype of glioblastoma and predict prognosis, efficacy of immunotherapy and radiotherapy. Front Immunol. 2021;12:729359. https:\/\/doi.org\/10.3389\/fimmu.2021.729359.","journal-title":"Front Immunol"},{"key":"12_CR72","doi-asserted-by":"publisher","first-page":"1303335","DOI":"10.3389\/fonc.2024.1303335","volume":"14","author":"X Wang","year":"2024","unstructured":"Wang X, Wang L, Lin H, Zhu Y, Huang D, Lai M, Xi X, Huang J, Zhang W, Zhong T. Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy. Front Oncol. 2024;14:1303335. https:\/\/doi.org\/10.3389\/fonc.2024.1303335.","journal-title":"Front Oncol"},{"issue":"7","key":"12_CR73","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.3390\/cells10071644","volume":"10","author":"S Iacobas","year":"2021","unstructured":"Iacobas S, Iacobas DA. A personalized genomics approach of the prostate cancer. Cells. 2021;10(7):1644. https:\/\/doi.org\/10.3390\/cells10071644.","journal-title":"Cells"},{"issue":"24","key":"12_CR74","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.21037\/atm-20-2920","volume":"8","author":"M Jiang","year":"2020","unstructured":"Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, He Y, Zhou C. Alterations of DNA damage repair in cancer: from mechanisms to applications. Ann Transl Med. 2020;8(24):1685. https:\/\/doi.org\/10.21037\/atm-20-2920.","journal-title":"Ann Transl Med"},{"issue":"1","key":"12_CR75","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41392-020-0196-9","volume":"5","author":"L Chen","year":"2020","unstructured":"Chen L, Liu S, Tao Y. Regulating tumor suppressor genes: post-translational modifications. Signal Transduct Target Ther. 2020;5(1):90. https:\/\/doi.org\/10.1038\/s41392-020-0196-9.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"12_CR76","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10585-023-10246-2","volume":"41","author":"W Liu","year":"2024","unstructured":"Liu W, Puri A, Fu D, Chen L, Wang C, Kellis M, Yang J. Dissecting the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics. Clin Exp Metastasis. 2024;41(4):313\u201332. https:\/\/doi.org\/10.1007\/s10585-023-10246-2.","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"12_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189233","volume":"1880","author":"P Garg","year":"2025","unstructured":"Garg P, Singhal G, Pareek S, Kulkarni P, Horne D, Nath A, Salgia R, Singhal SS. Unveiling the potential of gene editing techniques in revolutionizing cancer treatment: a comprehensive overview. Biochim Biophys Acta Rev Cancer. 2025;1880(1):189233. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189233.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"11","key":"12_CR78","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.18632\/aging.204115","volume":"14","author":"J Zhang","year":"2022","unstructured":"Zhang J, Ding X, Peng K, Jia Z, Yang J. Identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression. Aging. 2022;14(11):4839\u201357. https:\/\/doi.org\/10.18632\/aging.204115.","journal-title":"Aging"},{"key":"12_CR79","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3389\/fonc.2019.00884","volume":"9","author":"AN Boettcher","year":"2019","unstructured":"Boettcher AN, Usman A, Morgans A, VanderWeele DJ, Sosman J, Wu JD. Past, current, and future of immunotherapies for prostate cancer. Front Oncol. 2019;9:884. https:\/\/doi.org\/10.3389\/fonc.2019.00884.","journal-title":"Front Oncol"},{"issue":"12","key":"12_CR80","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.3390\/jcm13123466","volume":"13","author":"P Garg","year":"2024","unstructured":"Garg P, Pareek S, Kulkarni P, Salgia R, Singhal SS. Nanoengineering solutions for cancer therapy: bridging the gap between clinical practice and translational research. J Clin Med. 2024;13(12):3466. https:\/\/doi.org\/10.3390\/jcm13123466.","journal-title":"J Clin Med"},{"issue":"10","key":"12_CR81","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3390\/vaccines11101599","volume":"11","author":"L Ni","year":"2023","unstructured":"Ni L. Advances in mRNA-based cancer vaccines. Vaccine. 2023;11(10):1599. https:\/\/doi.org\/10.3390\/vaccines11101599.","journal-title":"Vaccine"},{"issue":"8","key":"12_CR82","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s43018-021-00241-5","volume":"2","author":"MC Milone","year":"2021","unstructured":"Milone MC, Xu J, Chen SJ, Collins MA, Zhou J, Powell DJ Jr, Melenhorst JJ. Engineering enhanced CAR T-cells for improved cancer therapy. Nat Can. 2021;2(8):780\u201393. https:\/\/doi.org\/10.1038\/s43018-021-00241-5.","journal-title":"Nat Can"},{"key":"12_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.982026","volume":"13","author":"L Yu","year":"2022","unstructured":"Yu L, Sun M, Zhang Q, Zhou Q, Wang Y. Harnessing the immune system by targeting immune checkpoints: providing new hope for oncotherapy. Front Immunol. 2022;13:982026. https:\/\/doi.org\/10.3389\/fimmu.2022.982026.","journal-title":"Front Immunol"},{"key":"12_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101530","volume":"25","author":"Y Su","year":"2022","unstructured":"Su Y, Su C, Qin L. Current landscape and perspective of oncolytic viruses and their combination therapies. Transl Oncol. 2022;25:101530. https:\/\/doi.org\/10.1016\/j.tranon.2022.101530.","journal-title":"Transl Oncol"},{"issue":"6","key":"12_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.189026","volume":"1878","author":"P Garg","year":"2023","unstructured":"Garg P, Mohanty A, Ramisetty S, Kulkarni P, Horne D, Pisick E, Salgia R, Singhal SS. Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers. Biochim Biophys Acta Rev Cancer. 2023;1878(6):189026. https:\/\/doi.org\/10.1016\/j.bbcan.2023.189026.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"12_CR86","doi-asserted-by":"publisher","first-page":"1076883","DOI":"10.3389\/fimmu.2022.1076883","volume":"13","author":"J Xie","year":"2023","unstructured":"Xie J, Luo X, Deng X, Tang Y, Tian W, Cheng H, Zhang J, Zou Y, Guo Z, Xie X. Advances in artificial intelligence to predict cancer immunotherapy efficacy. Front Immunol. 2023;13:1076883. https:\/\/doi.org\/10.3389\/fimmu.2022.1076883.","journal-title":"Front Immunol"},{"key":"12_CR87","doi-asserted-by":"publisher","first-page":"251513552413058","DOI":"10.1177\/25151355241305856","volume":"12","author":"M Shahzadi","year":"2024","unstructured":"Shahzadi M, Rafique H, Waheed A, Naz H, Waheed A, Zokirova FR, Khan H. Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives. Ther Adv Vaccines Immunother. 2024;12:25151355241305856. https:\/\/doi.org\/10.1177\/25151355241305856.","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"7","key":"12_CR88","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/bios14070356","volume":"14","author":"T Wasilewski","year":"2024","unstructured":"Wasilewski T, Kamysz W, G\u0119bicki J. AI-assisted detection of biomarkers by sensors and biosensors for early diagnosis and monitoring. Biosensors. 2024;14(7):356. https:\/\/doi.org\/10.3390\/bios14070356.","journal-title":"Biosensors"},{"issue":"22","key":"12_CR89","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.3390\/cancers16223884","volume":"16","author":"P Garg","year":"2024","unstructured":"Garg P, Singhal G, Kulkarni P, Horne D, Salgia R, Singhal SS. Artificial intelligence-driven computational approaches in the development of anticancer drugs. Cancer. 2024;16(22):3884. https:\/\/doi.org\/10.3390\/cancers16223884.","journal-title":"Cancer"},{"issue":"8","key":"12_CR90","first-page":"514","volume":"42","author":"CL Ventola","year":"2017","unstructured":"Ventola CL. Cancer immunotherapy, part 3: challenges and future trends. P & T. 2017;42(8):514\u201321.","journal-title":"P & T"},{"key":"12_CR91","doi-asserted-by":"publisher","first-page":"1397613","DOI":"10.3389\/fonc.2024.1397613","volume":"14","author":"FJ Medina-Olivares","year":"2024","unstructured":"Medina-Olivares FJ, G\u00f3mez-De Le\u00f3n A, Ghosh N. Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma. Front Oncol. 2024;14:1397613. https:\/\/doi.org\/10.3389\/fonc.2024.1397613.","journal-title":"Front Oncol"},{"issue":"5","key":"12_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103373","volume":"9","author":"L Vidal","year":"2024","unstructured":"Vidal L, Dlamini Z, Qian S, Rishi P, Karmo M, Joglekar N, Abedin S, Previs RA, Orbegoso C, Joshi C, Azim HA, Karkaria H, Harris M, Mehrotra R, Berraondo M, Werutsky G, Gupta S, Niikura N, Chico I, Saini KS. Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers. ESMO Open. 2024;9(5):103373. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103373.","journal-title":"ESMO Open"},{"issue":"Suppl 2","key":"12_CR93","doi-asserted-by":"publisher","DOI":"10.1111\/mcn.12728","volume":"15","author":"I Michaud-L\u00e9tourneau","year":"2019","unstructured":"Michaud-L\u00e9tourneau I, Gayard M, Mathisen R, Phan LTH, Weissman A, Pelletier DL. Enhancing governance and strengthening advocacy for policy change of large collective impact initiatives. Matern Child Nutr. 2019;15(Suppl 2):e12728. https:\/\/doi.org\/10.1111\/mcn.12728.","journal-title":"Matern Child Nutr"},{"key":"12_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217155","volume":"601","author":"D Liu","year":"2024","unstructured":"Liu D, Wang L, Guo Y. Advances in and prospects of immunotherapy for prostate cancer. Cancer Lett. 2024;601:217155. https:\/\/doi.org\/10.1016\/j.canlet.2024.217155.","journal-title":"Cancer Lett"},{"issue":"11","key":"12_CR95","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1016\/j.apsb.2021.02.007","volume":"11","author":"Z Xu","year":"2021","unstructured":"Xu Z, Wang X, Zeng S, Ren X, Yan Y, Gong Z. Applying artificial intelligence for cancer immunotherapy. Acta Pharm Sin B. 2021;11(11):3393\u2013405. https:\/\/doi.org\/10.1016\/j.apsb.2021.02.007.","journal-title":"Acta Pharm Sin B"}],"container-title":["Cancer Treatment and Research","Immunotherapies in Solid Tumors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-97242-3_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:32:57Z","timestamp":1778880777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-97242-3_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031972416","9783031972423"],"references-count":95,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-97242-3_12","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-3-031-97242-3","asserted-by":"object"}]},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"23 August 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}